Please login to the form below

Not currently logged in
Email:
Password:

ImmunoGen

This page shows the latest ImmunoGen news and features for those working in and with pharma, biotech and healthcare.

Takeda spends $230m on oncology biotech deal

Takeda spends $230m on oncology biotech deal

Takeda spends $230m on oncology biotech deal. Buys into ImmunoGen’ s antibody-drug conjugate technology. ... Japanese pharma company Takeda has signed a deal potentially worth $230m with ImmunoGen for two anticancer targets.

Latest news

More from news
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Termination. As part of its ongoing re-prioritisation and trimming of its oncology pipeline and correspondingly downsizing and reorganising the R&D teams, Sanofi is terminating its agreement with ImmunoGen and

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    265. Immunogen / Takeda. Licence and collaboration option. Antibody-drug conjugate (ADC) technology to develop 2 anticancer products option on 3rd.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    240.5. ImmunoGen / Novartis. Licence. ADC technology - extension of 2010 agreement.

  • Pharma deals during October 2013 Pharma deals during October 2013

    This month ImmunoGen and Novartis announced a second licence under their 2010 agreement giving Novartis rights to the biotech's ADC technology to develop anticancer therapeutics to an undisclosed target. ... ImmunoGen could receive around $200m in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics